- Home
- DSP vs ENGN Comparison
DSP vs ENGN Comparison
Compare DSP & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ENGN
- Stock Information
- Founded
- DSP 1999
- ENGN 1999
- Country
- DSP United States
- ENGN Canada
- Employees
- DSP N/A
- ENGN N/A
- Industry
- DSP EDP Services
- ENGN
- Sector
- DSP Technology
- ENGN
- Exchange
- DSP Nasdaq
- ENGN Nasdaq
- Market Cap
- DSP 220.3M
- ENGN 191.1M
- IPO Year
- DSP 2021
- ENGN N/A
- Fundamental
- Price
- DSP $10.30
- ENGN $5.18
- Analyst Decision
- DSP Strong Buy
- ENGN Buy
- Analyst Count
- DSP 9
- ENGN 7
- Target Price
- DSP $20.44
- ENGN $23.29
- AVG Volume (30 Days)
- DSP 347.0K
- ENGN 170.9K
- Earning Date
- DSP 08-11-2025
- ENGN 09-09-2025
- Dividend Yield
- DSP N/A
- ENGN N/A
- EPS Growth
- DSP N/A
- ENGN N/A
- EPS
- DSP 0.13
- ENGN N/A
- Revenue
- DSP $318,471,000.00
- ENGN N/A
- Revenue This Year
- DSP $16.28
- ENGN N/A
- Revenue Next Year
- DSP $15.43
- ENGN N/A
- P/E Ratio
- DSP $77.09
- ENGN N/A
- Revenue Growth
- DSP 30.92
- ENGN N/A
- 52 Week Low
- DSP $9.07
- ENGN $2.65
- 52 Week High
- DSP $26.33
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- DSP 42.79
- ENGN 80.06
- Support Level
- DSP $9.81
- ENGN $4.24
- Resistance Level
- DSP $10.35
- ENGN $3.89
- Average True Range (ATR)
- DSP 0.43
- ENGN 0.36
- MACD
- DSP 0.16
- ENGN 0.11
- Stochastic Oscillator
- DSP 84.25
- ENGN 97.16
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.